<DOC>
	<DOCNO>NCT00266461</DOCNO>
	<brief_summary>Postoperative ileus ( POI ) , transient impairment gastrointestinal ( GI ) motility , commonly occur patient undergone abdominal surgery contributes postoperative morbidity , include delayed enteral nutrition , increase patient discomfort , prolonged hospitalization . POI appear many cause , activation inhibitory reflex , inflammatory response , effect anesthesia analgesic play role . However , approve pharmacological therapy treatment prevention POI . Daikenchuto ( TU-100 ) herbal formulation consist Asian ginseng , Zanthoxylum fruit ( Sichuan pepper ) , ginger , malt sugar , originally describe Jin kui yao lue , classical medical textbook write ancient China third century Zhang Zhong Jing . Since introduce Japan , Daikenchuto use treatment abdominal pain feeling coldness abdomen . TSUMURA Daikenchuto Extract Granules , Product Code TU-100 , modern herbal product manufacture dosage form granule Tsumura &amp; Co . The current Tsumura product , TU-100 , approve manufacture prescription drug 1986 Japanese Ministry Health Welfare sell commercially prescription Kampo ( generic term system traditional medicine develop Japan introduce China fourth century ) drug Japan many year . The drug product propose use clinical study identical drug currently sell Japan . In addition , three botanical component maltose syrup powder consider food substance currently part United States food supply . The purpose study evaluate tolerability , efficacy safety TU-100 treatment postoperative ileus ( POI ) patient undergo laparotomy large bowel resection</brief_summary>
	<brief_title>A Tolerability Efficacy Study TU-100 For The Treatment Postoperative Ileus</brief_title>
	<detailed_description>This randomize , control , open-label study design evaluate tolerability efficacy TU-100 treatment POI patient undergo laparotomy large bowel resection . It conduct multiple center United States . A total 24 patient enrol study . Patient participation study last 32 day ( Screening postoperative day 10 [ POD 10 ] time discharge order write patient , whichever come first ) , follow-up safety assessment occur 7 14 day last dose study medication .</detailed_description>
	<mesh_term>Ileus</mesh_term>
	<criteria>In order participate study , patient must meet following criterion : 1 . Is least 18 year age ; 2 . Is male female . Female patient pregnant lactate must surgically sterile , postmenopausal ( menses previous 12 month ) , practice effective method birth control determine investigator ( eg , oral contraceptive , double barrier method , hormonal injectable implantable contraceptive , tubal ligation , partner vasectomy ) ; 3 . Has diagnose sigmoid carcinoma ; ascend , transverse , descend colon carcinoma ; colonic polyp ; carcinoid tumor ; lymphoma localized abdomen ; ischemic bowel ; toxic megacolon perforation ; tumor bowel determine require removal ; diverticulitis ; 4 . Requires laparotomy large bowel resection . Note : patient shift laparotomy laparoscopic surgery acceptable ; 5 . Is hospitalize surgery recovery ; 6 . Has preoperative Karnofsky performance status 80 % 100 % ; 7 . Provides write informed consent prior participation study full explanation study purpose procedure . In order participate study , patient must meet following criterion : 1 . Has diagnose Crohn 's disease , ulcerative colitis , irritable bowel syndrome . Note : patient inactive ulcerative colitis stable clinical remission and/or maintenance therapy prevent relapse acceptable ; 2 . Is pregnant lactate female ; 3 . Requires colostomy ostomy device placement ; 4 . Requires emergency surgery surgery presence ongoing infection , include bowel obstruction perforate bowel ; 5 . Has colorectal cancer Dukes Classification score D ; 6 . Has diabetic neuropathy ; 7 . Has history gastroparesis ; 8 . Has compromise immune system , either treatment corticosteroid immunosuppressive agent within 2 week surgery immunosuppressive disease ( eg , human immunodeficiency virus ) ; Note : patient chronic treatment ( least 3 month ) corticosteroids 10 mg daily prednisone equivalent acceptable dose stable least 2 week ; 9 . Has serious condition might adversely affect safety ability participate study , liver disorder ( include alanine aminotransferase [ ALT ] and/or aspartate aminotransferase [ AST ] level great 2.5 time upper limit normal [ ULN ] ) , kidney disorder , heart failure , blood disorder , metabolic disorder ; 10 . Has history allergic reaction ginseng , ginger , Zanthoxylum fruit ( Sichuan pepper ) , maltose ; 11 . Has history narcotic drug abuse ( especially heroin opium ) chronic narcotic use pain management within 2 week surgery ; 12 . Requires anticancer radiation chemotherapy within 2 week surgery ; 13 . Has history laparotomy laparoscopy simple laparoscopic procedure cholecystectomy , gynecological procedure , inguinal hernia repair . Note : history laparoscopic fundoplication exclusive , history appendectomy hysterectomy acceptable ; patient laparotomy procedure past history subsequent small bowel large bowel obstruction acceptable ; 14 . Has history type ileus ; 15 . Has history receive abdominal radiation therapy addition subsequent small bowel large bowel obstruction . Note : history radiation therapy small bowel large bowel obstruction acceptable ; history pelvic radiation therapy also acceptable ; 16 . Is unwilling unable comply procedure describe protocol otherwise unacceptable enrollment opinion investigator ; 17 . Has participate investigational product device trial within 30 day prior enrol study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Postoperative Ileus</keyword>
</DOC>